1. Scrip

Departing Words: Merck’s Ken Frazier Cautions Against Profit Maximization

 
• By Sarah Karlin-Smith

Pharma CEOs must balance optimizing access and profitability, former Merck CEO and soon-to-be ex executive chairman of the company said. Frazier says health care industry must come to table and admit the “system ain’t working,” talks about the need to protect democracy, in a sweeping interview at the STAT Summit.

Kenneth Frazier, Chairman of the Board and CEO of US pharmaceutical company Merck looks on during an event with the French-American Foundation in Paris on July 11, 2018. (Photo by ERIC PIERMONT / AFP) GettyImages-996036844
• Source: Eric Piermont/AFP via Getty Images

Drug industry CEOs must operate differently than the leaders of other businesses due to the role of medicines and ethics around medicine, said Merck & Co., Inc.’s outgoing executive chairman and former CEO Ken Frazier in a 16 November interview just two weeks ahead of his retirement from the pharmaceutical company.

“My personal view is that pharma CEOs can’t simply take the attitude that they are going to maximize financial outcomes,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.